Inceptionr LLC Sells 15,928 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Inceptionr LLC trimmed its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 27.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 41,921 shares of the company’s stock after selling 15,928 shares during the quarter. Inceptionr LLC’s holdings in Amneal Pharmaceuticals were worth $332,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Raymond James Financial Inc. bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $2,946,000. Arizona State Retirement System grew its position in shares of Amneal Pharmaceuticals by 13.6% in the 4th quarter. Arizona State Retirement System now owns 40,401 shares of the company’s stock worth $320,000 after buying an additional 4,851 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Amneal Pharmaceuticals by 112.8% in the 4th quarter. Victory Capital Management Inc. now owns 211,130 shares of the company’s stock worth $1,672,000 after buying an additional 111,915 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Amneal Pharmaceuticals by 9.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,539,934 shares of the company’s stock worth $12,196,000 after buying an additional 135,051 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd grew its position in shares of Amneal Pharmaceuticals by 55.3% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 58,111 shares of the company’s stock worth $460,000 after buying an additional 20,686 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Barclays lifted their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Finally, Piper Sandler raised their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $10.80.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 62,590 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total transaction of $501,345.90. Following the completion of the transaction, the director now owns 1,968,886 shares in the company, valued at approximately $15,770,776.86. The trade was a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 240,000 shares of company stock worth $2,004,000. 26.56% of the stock is owned by insiders.

Amneal Pharmaceuticals Stock Up 1.6 %

AMRX opened at $8.90 on Monday. The stock has a market cap of $2.76 billion, a PE ratio of -13.09 and a beta of 1.05. The business has a 50 day moving average of $8.20 and a 200-day moving average of $8.35. Amneal Pharmaceuticals, Inc. has a 52 week low of $5.18 and a 52 week high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The company had revenue of $730.52 million for the quarter, compared to analysts’ expectations of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same quarter in the previous year, the firm posted $0.14 EPS. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.